5-Oxo-11-hydroxy voaphylline






Names

    • 5-Oxo-11-hydroxy voaphylline

Attributes

  • Canonical SMILES

    CC[C@]12CCC3=C(C4=CC=C(O)C=C4N3)CC(N(C[C@@H]5[C@H]2O5)C1)=O

  • InChI

    InChI=1S/C19H22N2O3/c1-2-19-6-5-14-13(12-4-3-11(22)7-15(12)20-14)8-17(23)21(10-19)9-16-18(19)24-16/h3-4,7,16,18,20,22H,2,5-6,8-10H2,1H3/t16-,18-,19+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 68.86
  • #RotBonds: 1
  • MW: 326.3960000000001
  • HBD: 2
  • HBA: 3
  • logP: 2.3682
  • Chemical Formula: C19H22N2O3


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. divaricata China, Japan, Thailand, Bangladesh, Vienna 52861 BBP0671

External Databases


References

  • Virtual Screening of compounds from Tabernaemontana divaricata for potential anti-bacterial activity. Bioinformation, 2014 (PMID 24748755).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Antibacterial

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.22
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -5.17
    Human Oral Bioavailability 50% Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Non-Substrate
    Skin Permeability -1.9
    Distribution Blood-Brain Barrier (Central Nervous System) -2.95
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.4
    Plasma Protein Binding 32.44
    Steady State Volume of Distribution 2.38
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 19.81
    Organic Cation Transporter 2 Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Toxic
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 0.09
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.74
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 3.73
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Toxic
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -1.9
    Rat (Acute) 2.2
    Rat (Chronic Oral) 2.18
    Fathead Minnow 3.98
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 477.87
    Hydration Free Energy -8.26
    Log(D) at pH=7.4 0.74
    Log(P) 1.56
    Log S -3.36
    Log(Vapor Pressure) -10.09
    Melting Point 291.29
    pKa Acid 7.29
    pKa Basic 7.52